Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.
The death today of Sen. John McCain (R-Ariz.) sheds a new light on glioblastoma, a form of brain cancer that the American Brain Tumor Association estimated would be diagnosed in nearly 13,000 people this year.
There are many lawmakers who made their names in health care, seeking to usher through historic changes to a broken system.
Certain brain cancers are associated with low numbers of immune system T-cells circulating in the peripheral blood. Low T-cell numbers can be a side-effect of cancer treatment. But it now appears that there is more to the story of these missing T-cells.
The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain's security system, helping to safeguard the brain and regulate the flow of substances into and out of it.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.
In the first such clinical trial in the United States, physician-scientists with the University of Maryland School of Medicine are investigating the use of MRI-guided focused ultrasound to open the blood-brain barrier.
A new study by KAIST researchers identified where the mutation causing glioblastoma starts. According to the study, neural stem cells away from the tumor mass are the cells of origin that contain mutation drivers for glioblastoma, one of the most aggressive brain tumor
In a "proof of concept" study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice.
Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center have discovered how different mutations in a specific gene help drive glioblastoma, the most lethal form of brain cancer.
A drug used to treat altitude sickness -- as well as glaucoma, epilepsy, heart failure and seizures -- may also offer significant gains for patients with a fast-growing brain tumor known as glioblastoma, according to a study published July 4, 2018, in the journal Science Translational Medicine.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.
Interstitial fluid transports nutrients and removes waste between the organs and tissues in our body. In the brain, interstitial fluid is thought to be composed of circulating cerebrospinal fluid, cellular waste and blood plasma, and past research has shown a link between interstitial fluid flow and an increased invasion rate of glioblastoma, or brain tumor, cells.
A viral immunotherapy using a herpes virus to treat brain tumors has been shown to be safe and well-tolerated in a pediatric study from the University of Alabama at Birmingham and Children's of Alabama.
The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.
Glioma is the most common type of primary malignant brain tumor in the United States; glioblastoma being the most common type of glioma in adults.
A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Salk Institute scientists Ronald Evans, Diana Hargreaves, Tony Hunter, Graham McVicker and Geoffrey Wahl are among the first wave of researchers to receive funding from Padres Pedal the Cause, one of one of the largest stand-alone cancer fundraising events in San Diego.
According to researchers genetically altered poliovirus strains could help some patients of brain cancer. A team of researchers from Duke University in Durham, North Carolina, used modified polio virus strains in small groups of patients who had glioblastoma – a particularly deadly form of brain cancer. In these patients standard treatments have failed say the researchers and this novel therapy could help.
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.